---
title: "CARsgen says NMPA clears IND for CT1190B in relapsed/refractory large B-cell lymphoma"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295158160.md"
description: "CARsgen Therapeutics received NMPA IND clearance for CT1190B, an allogeneic CD19/CD20 CAR-T therapy, to treat relapsed or refractory large B-cell lymphoma patients who failed at least two prior therapies. The drug utilizes the THANK-u Plus platform."
datetime: "2026-08-07T00:00:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295158160.md)
  - [en](https://longbridge.com/en/news/295158160.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295158160.md)
generator: "portal-rs"
---

# CARsgen says NMPA clears IND for CT1190B in relapsed/refractory large B-cell lymphoma

-   CARsgen won NMPA IND clearance for CT1190B in relapsed or refractory large B-cell lymphoma patients who failed at least two prior therapy lines. \* CT1190B is an allogeneic CD19/CD20 CAR-T therapy built on the THANK-u Plus platform. \* Investigator-initiated trial results were presented at the 2026 European Hematology Association congress. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CARsgen Therapeutics Holdings Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260807-12276467), on August 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [02171.HK](https://longbridge.com/en/quote/02171.HK.md)
- [00388.HK](https://longbridge.com/en/quote/00388.HK.md)
- [80388.HK](https://longbridge.com/en/quote/80388.HK.md)
- [HKXCY.US](https://longbridge.com/en/quote/HKXCY.US.md)

## Related News & Research

- [CARsgen says CT0596 wins NMPA IND clearance for relapsed/refractory multiple myeloma](https://longbridge.com/en/news/294748631.md)
- [World’s First Solid-Tumor CAR-T Therapy Begins Rollout in China With First Foreign Patient](https://longbridge.com/en/news/296349187.md)
- [The Bull Case For Natera (NTRA) Could Change Following New Signatera Lymphoma Data And Komen Partnership](https://longbridge.com/en/news/298111249.md)
- [MicroPort FireShield coronary covered stent enters China NMPA innovative device review channel](https://longbridge.com/en/news/297780832.md)
- [Impact Therapeutics says senaparib EU marketing application under EMA review, approval eyed in 2H 2026](https://longbridge.com/en/news/297485071.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**